Pharmaceutical drug regulatory affairs is the function that gets a medicine registered with agencies such as the FDA and EMA, then keeps it compliant from research and development through clinical trials, approval, manufacturing, labelling and postmarket surveillance. The work includes preparing submissions and maintaining the dossier behind them. AI now drafts parts of that dossier quickly, but a published study of IND drafting shows the drafts are first drafts that still need expert regulatory writing to reach submission quality. If you need the basic picture first, our guide to what regulatory affairs is in a pharmaceutical company covers it; this page is about the dossier and where automation stops.
What does regulatory affairs do in a pharmaceutical company, and how does it work in practice?
The regulatory affairs function makes sure the company complies with the laws and regulations that apply to its products, and it is the company’s working interface with agencies like the FDA and EMA on specific issues. Its most significant responsibility is getting a product registered and approved, and the work includes preparing submissions. The work starts long before a filing and continues long after one, from early development to postmarket surveillance.
The submission itself follows a set structure. The Common Technical Document (CTD) is organised into five modules: Module 1 is region-specific, and Modules 2 to 5 are intended to be common across regions. Module 2 carries the summaries, Module 3 quality, Module 4 nonclinical study reports and Module 5 clinical study reports.
ICH M4, as published by the FDA, says that once an applicant picks a document granularity it should keep that approach for the life of the dossier, because changed information is supplied as replacement documents or files. For study reports in Modules 4 and 5, the guidance repeats the point: when relevant information changes at any point in the product’s lifecycle, replacements of complete documents should be provided.
A dossier is not written once; it is a living set of documents where each replacement has to be consistent with everything around it, and where a summary in Module 2 must still match the study reports it summarises after both have been revised.
What does a regulatory affairs specialist actually do day-to-day in a pharma company, and how does that map to the claim-bearing surfaces an automation rollout must respect?
The O*NET occupational profile for regulatory affairs specialists lists the core tasks as coordinating, preparing or reviewing regulatory submissions, coordinating the preparation of regulatory documents, and providing technical review of data or reports so that submissions have scientific rigour, accuracy and clarity. It also names evaluating information to determine compliance with standards, using relevant information and individual judgement. In the same profile, 67% of respondents rated being exact or accurate as “extremely important” to the job.
The table below pairs each O*NET task with our reading of where an automation rollout should draw its line.
| Specialist task | Claim-bearing surface it touches | Where the automation line sits |
|---|---|---|
| Coordinating preparation of regulatory documents and submissions | Dossier structure, granularity and lifecycle replacements | Tracking, assembly and consistency checks can be automated; the decision to replace a document stays human |
| Preparing submissions | Module 2 written summaries, cover letters, responses to agency questions | AI can produce a first draft from source documents; the specialist owns what it emphasises and concludes |
| Technical review of data or reports for rigour, accuracy and clarity | Study data and results carried into Modules 2 to 5 | AI can flag inconsistencies against sources; the reviewer decides whether the data supports the statement |
| Evaluating compliance using individual judgement | Labelling, attestations, compliance positions | Not a drafting task; this is the judgement the role exists to exercise |
The table is deliberately about tasks rather than job titles. Career questions about the role belong elsewhere; what matters for an automation project is that O*NET lists preparing and reviewing submissions as tasks of the same role.
Which parts of a regulatory submission always need human judgement?
The claim-bearing surfaces are the places where the dossier tells a regulator what the evidence means: the Module 2 summaries and overviews, the labelling, the conclusions drawn about safety and efficacy, and any statement someone signs as true. A useful test comes from the AutoIND study, which defined a critical regulatory error as any misrepresentation or omission likely to alter regulatory interpretation of safety, efficacy or compliance, such as an incorrect NOAEL attribution. Anything on which such an error could land is a surface that needs a human decision, not just a human glance.
The FDA’s own framing points the same way. An FDA presentation on data integrity in application submissions calls the integrity and quality of submitted data critical concerns, and describes reviewers deciding whether data is reliable, requesting for-cause inspections and investigating anomalies such as unusually similar PK profiles. The same presentation notes that applicants most often meet data integrity problems after an FDA inspection, late in review, with lengthy approval delays as the result. A team that delegates its own scrutiny to a drafting tool is moving the moment of discovery to the worst possible place.
An AI draft of a claim-bearing section should be evidence for a human decision, never the decision itself.
In the EMA guideline on computerised systems in clinical trials, an investigator’s signature is the documented confirmation that the data the investigator entered and submitted to the sponsor are attributable, legible, original, accurate, complete and contemporaneous. No model can give that confirmation on someone’s behalf.
Where does AI actually fit in pharmaceutical drug regulatory affairs?
AI fits at compiling and drafting: turning large volumes of source documents into a first draft while human experts provide oversight. In the AutoIND study, AutoIND (part of the Weave Platform) cut initial drafting time for IND written summaries by 97%, from roughly 100 hours to 3.7 hours for 18,870 pages of source documents in one IND and to 2.6 hours for 11,425 pages in the other. The summaries covered eCTD Modules 2.6.2, 2.6.4 and 2.6.6 (pharmacology, pharmacokinetics and toxicology).
The quality numbers are where the boundary shows. The drafts scored 69.58% and 77.85% against submission-ready quality, and no critical regulatory errors were detected. Correctness stayed above 89% across modules, but emphasis scored uniformly low, falling to 6.7% for toxicology in one IND, because the tool over-described methods and under-weighted results. Expert review found 3 to 5 times word-count inflation, 35% of summaries missing essential study design elements and a 100% omission rate for GLP-required dose formulation analysis. Reviewers also found hallucinated regulatory conclusions, including NOAEL values assigned to in-vitro studies.
The authors’ own conclusion is that current systems generate surface-level drafts rather than submission-ready documents, and that expert regulatory writing is still needed to bring output to submission quality. They also note the results may not carry over to clinical protocols, manufacturing information or other IND sections with different complexity. One study on three nonclinical modules is a strong signal about drafting, not a general verdict on AI in regulatory work.
Drafting assistance versus decision automation
We draw the line between drafting assistance and decision automation at whether a qualified person reviews, verifies and accepts the output before it becomes a regulated record. The AutoIND authors propose a five-step flow (ingest, draft, refine and review with expert judgement, verify by tracing information to sources, then publish) in which the human steps sit between the draft and the filing. A 2026 paper on agentic digitisation of batch manufacturing records takes the same stance: the system is a human-in-the-loop augmentation tool, all extracted output needs qualified review before entering validated systems, and ambiguous content is flagged for review rather than assumed. The same authors name automation bias as a risk and deliberately make their confidence scoring conservative to counter it.
We would treat automation bias as the main design problem, not a footnote. A reviewer who sees fluent, mostly correct text is primed to approve it, and the AutoIND failure mode (correct facts, wrong emphasis) is exactly the kind a tired reviewer misses. The deeper treatment of where review becomes adjudication sits in our piece on the drafting versus adjudication boundary, and a section-level walk-through is in the worked example of AI-assisted drafting of a submission section.
Workflows that are realistic candidates today
On the evidence available, the candidates tested so far are nonclinical written summaries drafted from study reports and structured extraction from legacy batch records, where calculations and conditional logic were captured with full fidelity but handwritten annotations and multi-page narratives still needed review. EMA and HMA also describe querying large document sets and knowledge mining as LLM uses on the regulator side. Labelling decisions, compliance positions and responses that commit the company to an interpretation are not on that list.
How do FDA and EMA guidance shape what regulatory affairs teams can safely automate?
Guidance shapes automation by making it risk-based: the FDA recommends basing validation and audit-trail decisions on a system’s potential to affect product quality, safety and record integrity. The FDA’s January 2025 draft guidance on AI in drug and biologics regulation sets out a risk-based credibility assessment framework; our hub on AI in regulatory affairs and GxP explains that guidance and Part 11 scope in detail.
On the European side, EMA adopted its reflection paper on AI in the medicinal product lifecycle on 30 September 2024, covering AI and machine learning at any step from drug discovery to the post-authorisation setting. EMA and the FDA have since jointly identified ten principles for good AI practice across the medicines lifecycle, relevant to developers and to marketing authorisation applicants and holders, and framed around expert management and risk mitigation. EMA and HMA guidance for regulators’ own LLM use names hallucinations, variable results and data security as risks, and calls for defined governance, permitted use cases, training and risk monitoring.
Our reading is that a drafting assistant with expert review is easy to defend and an unreviewed generator of conclusions is not.
Why an AI submission tool needs validation
Validation matters because, under EMA’s clinical-trials guideline, the responsible party rather than the vendor answers for the system. The EMA guideline on computerised systems in clinical trials says such systems should be validated whether built in-house, bought or provided as a service, and that the responsible party remains ultimately responsible even when relying on vendor documentation. It defines validation as documenting that a system consistently meets its specified requirements, with a risk-based approach tied to intended use. The FDA’s Part 11 scope guidance likewise recommends basing validation decisions on a justified, documented risk assessment of the system’s potential to affect product quality, safety and record integrity. For an LLM-based tool, that means the test cases have to cover the failure modes the AutoIND reviewers found, not only whether the software runs.
How does regulatory affairs preserve the audit trail across a submission’s lifecycle?
Preserving the audit trail means making sure every change to a regulated electronic record is captured independently of the person making it and kept as long as the record. 21 CFR 11.10(e) requires secure, computer-generated, time-stamped audit trails that record operator entries and actions creating, modifying or deleting electronic records, without obscuring earlier information. The FDA’s scope guidance exercises enforcement discretion on the audit-trail requirements of § 11.10(e) and (k)(2), but predicate-rule obligations still apply, including that changes must not obscure previous entries.
The EMA guideline spells out the content: initial entry and changes, previous and current values, which field, by whom, when and, where applicable, why. It also lists audit trails and event logs among the metadata an archive must allow restoring, and says data, context and audit trail should not be separated, including during migration. An event log that records that a user logged in or a job ran is not an audit trail of what changed in a record.
AI adds two pressures here. Each AI-assisted draft is a new link in the chain from source to submitted text, so the trail has to show which source the model used, what it produced and what the human changed before the CTD replacement document went out. And the logs themselves carry risk: the batch-record paper notes that audit logs needed for compliance can become routes for information leakage and need access controls and retention policies. The full lineage and versioning design is covered in our article on audit-ready data lineage and model versioning, and pre-inspection checks in how to audit AI-assisted regulatory content before an agency review.
Does using AI reduce a company’s regulatory burden?
AI can reduce drafting effort, but responsibility stays with the company, and the system itself has to be validated. The EMA guideline is direct on this: tasks can be delegated to a service provider, but full responsibility for data integrity, security and confidentiality stays with the responsible party, who must be able to show inspectors validation and operation evidence regardless of who did the work. A formal change control process with risk assessment applies when the system changes; we would treat model and prompt updates as such changes.
The AutoIND hours saved are real, but the authors still require expert review and verification against sources before publishing.
Who builds the evidence an AI drafting tool needs before regulatory affairs will rely on it?
TechnoLynx builds the engineering evidence a regulatory team, auditor or compliance owner needs to sign against an AI system: task-specific evaluations of the model on the documents it will draft, governance evidence packs aligned to named published rubrics such as NIST AI RMF and GxP references, and lineage and traceability for what the system produced. That work is engineering, not policy advice: it produces the artefacts an audit needs, and it is not legal advice, regulatory sign-off or certification. Our AI engineering for life sciences and healthcare page describes how we approach regulated workloads.
That boundary matters for who should call us. A team that needs a regulatory strategy, a submission written or an opinion on whether a filing will be accepted needs regulatory consultants or experienced in-house regulatory writers, and the AI evidence is secondary to that. Where a team already has the regulatory expertise and needs to know whether its drafting tool is fit to sit in the workflow, the evaluation and the traceability are the gap we would expect to fill.
FAQ
Is FDA guidance binding?
FDA guidance documents describe the agency’s current thinking and are not legally binding in the way regulations are. The underlying regulations, such as the predicate rules behind Part 11, still apply and are enforced regardless of how a guidance document frames discretion.
